Voriconazole-d3
(Synonyms: VRC-d3) 目录号 : GC48254具有多种生物活性的神经肽
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Voriconazole-d3 is intended for use as an internal standard for the quantification of voriconazole by GC- or LC-MS. Voriconazole is a triazole antifungal agent and a derivative of fluconazole .[1],[2] It is active against a variety of yeast and fungi, including clinical isolates of A. flavus, A. fumigatus, F. oxysporum, F. solani, C. albicans, and C. neoformans (MICs = 1 Voriconazole is also active against 56 clinical isolates of fluconazole-resistant C. albicans (MICs = 0.015-8 µg/ml).[2] It inhibits ergosterol biosynthesis in C. albicans, C. glabrata, A. fumigatus, and A. flavus (IC50s = 0.03-1 µg/ml).[3] Voriconazole (10 mg/kg twice per day, i.v.) decreases the number of lung colony-forming units (CFUs), reduces alveolar collapse and lung inflammatory cell infiltration and necrosis, and increases survival in a rat model of invasive pulmonary aspergillosis.[4] Formulations containing voriconazole have been used in the treatment of fungal infections.
Reference:
[1].Espinel-Ingroff, A.In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogensJ. Clin. Microbiol.36(1)198-202(1998)
[2].Cuenca-Estrella, M., DÍaz-Guerra, T.M., Mellado, E., et al.Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from SpainEur. J. Clin. Microbiol. Infect. Dis.18(6)432-435(1999)
[3].Munayyer, H.K., Mann, P.A., Chau, A.S., et al.Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and moldsAntimicrob. Agents Chemother.48(10)3690-3696(2004)
[4].Zhang, M., Su, X., Sun, W.-K., et al.Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus speciesMycopathologia177(1-2)11-18(2014)
| Cas No. | N/A | SDF | |
| 别名 | VRC-d3 | ||
| 化学名 | (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-4,4,4-d3-2-ol | ||
| Canonical SMILES | FC1=CN=CN=C1[C@@H]([C@](O)(CN2N=CN=C2)C3=C(C=C(C=C3)F)F)C([2H])([2H])[2H] | ||
| 分子式 | C16H11D3F3N5O | 分子量 | 352.3 |
| 溶解度 | DMSO: 20 mg/ml,Ethanol: 20 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8385 mL | 14.1924 mL | 28.3849 mL |
| 5 mM | 0.5677 mL | 2.8385 mL | 5.677 mL |
| 10 mM | 0.2838 mL | 1.4192 mL | 2.8385 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Simultaneous Determination of Voriconazole and Its Voriconazole N-Oxide Metabolite in Human Urine by Liquid Chromatography/Tandem Mass Spectrometry
J Chromatogr Sci 2022 Oct 3;60(8):800-806.PMID:34761250DOI:10.1093/chromsci/bmab126
A convenient and sensitive liquid chromatography-tandem mass spectrometry method was established to simultaneously quantify voriconazole (VRZ) and its metabolite, voriconazole N-oxide (VNO), in human urine. Voriconazole-d3 and Voriconazole-d3 N-oxide were used as isotopic internal standards. Samples were processed by protein precipitation and separated using a ZORBAX SB-Aq column (1.8 μm, 2.1 × 50 mm). Mass spectrometry was performed using an API 4000 mass spectrometry by positive electrospray ionization. The flow rate was 0.6 mL/min. Gradient elution was performed with methanol and 0.1% formic acid as the organic and water phase, respectively. The VRZ and VNO calibration curves ranged from 20.0 to 7200 ng/mL in human urine. The specificity, matrix effect, extraction recovery, intra/inter-run precision, accuracy and stability were validated for both VRZ and VNO in human urine. The developed method was used to study urinary excretion after intravenous injection of 4 mg/kg VRZ in healthy Chinese subjects.